Our study suggests that several immune checkpoints like PD‐L1, TIM‐3, and GAL‐9 strongly increase in acute COVID‐19 but decrease and virtually normalize during follow‐up, suggesting that they could be good tools to improve the current options battery for COVID‐19 diagnosis. The gene discussed is LGALS9; the disease is COVID-19.